Q-omics provides the consensus-scored NEFLP1 profile across patient tissues and cancer cell-line models. NEFLP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NEFLP1 is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, NEFLP1 RNA expression shows 6,075 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, KIRP, and HNSC as cancer lineages where NEFLP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEFLP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEFLP1 survival associations across molecular data types. NEFLP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEFLP1 RNA expression–survival associations across cancer types. High NEFLP1 expression shows unfavorable associations in LIHC, STAD, LUAD and DLBC, but favorable associations in ESCA and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NEFLP1 RNA expression.
This table summarizes NEFLP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NEFLP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEFLP1 shows lower tumor expression in KIRP. The KIRP box plot shows higher NEFLP1 RNA expression in normal versus tumor tissue (log2 FC = −0.021, t-test p = .039).
This table shows molecular features associated with NEFLP1 in patient tissues and cancer cell lines. In patient samples, NEFLP1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
